Zydus Cadila has received the final approval from the USFDA to market Entecavir Tablets in the strengths of 0.5 mg and 1 mg.

The drug is used in the treatment of Hepatitis B Virus infection and will be produced at the group's formulations manufacturing facility at the pharma SEZ in Ahmedabad. The estimated sale for Entecavir tablets is USD 166.3 million (1MS MAT April 2017).

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 4.05, or 0.77%, to trade at  Rs 529.15.  The total volume of shares traded  was  33,837 at the BSE (10.01 a.m., Tuesday).